Business Context and Reporting Period
Healthcare Triangle, Inc. (HCTI), a Delaware corporation listed on The Nasdaq Stock Market, filed this Form 8-K on November 20, 2025. The report details the entry into a Material Definitive Agreement involving a private placement of senior unsecured convertible promissory notes.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $6,000,000 received from the Initial Tranche.
- Debt Issuance: Initial principal amount of $7,500,000 in 20% original issue discount (OID) senior unsecured convertible notes.
- Total Potential Debt: Up to $15,000,000 aggregate principal amount (subject to conditions and investor approval).
- Interest Rate: 18% per annum on unpaid amounts (past due rate).
- Maturity Date: November 20, 2026.
- Conversion Price: The greater of 80% of the lowest closing price during the five trading days preceding conversion or $0.38 per share.
- Transaction Costs: 8.0% cash fee of gross proceeds plus $100,000 for legal fees and expenses paid to the placement agent.
Material Changes and Obligations
The filing represents a material change in the Company's capital structure through the creation of a direct financial obligation. The Company has entered into a Registration Rights Agreement requiring the filing of a registration statement within 10 calendar days and effectiveness within 60 days to cover the resale of conversion shares. Failure to meet these deadlines incurs liquidated damages of 2% per month, capped at 20%.
Outlook, Risks, and Contingencies
- Second Tranche Conditions: The remaining $7,500,000 tranche is contingent upon the satisfaction of conditions precedent, including an effective registration statement for the resale of shares.
- Liquidated Damages: Failure to deliver shares upon conversion notice within one trading day results in damages of 2% of the outstanding principal per month.
- Default Provisions: Upon an uncured Event of Default, the Mandatory Default Amount becomes immediately due and payable.
- Regulatory Compliance: The Company must use commercially reasonable efforts to obtain stockholder approval for share issuance in accordance with Nasdaq Listing Rules.
Investor Verification Checklist
- Verify the effectiveness of the registration statement for the resale of conversion shares within the 60-day deadline to avoid liquidated damages.
- Confirm the Company's ability to meet the 18% interest obligation and the 2% monthly penalty for delayed share delivery.
- Assess the dilution impact based on the conversion price floor of $0.38 per share versus current market prices.
- Review the conditions precedent required to trigger the issuance of the second $7,500,000 tranche.
- Check for any pending stockholder approval requirements under Nasdaq Listing Rules regarding the issuance of shares upon conversion.